FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results

By adminFebruary 18, 2023Global News Feed

SAN FRANCISCO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2022 financial results on Monday, February 27 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.

Read more:
FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results

OpGen Announces Exercise of All Prefunded Warrants

By adminFebruary 18, 2023Global News Feed

ROCKVILLE, Md., Feb. 17, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced that all of the prefunded warrants that were issued in its public offering that closed on January 11, 2023 have been exercised in full. In light of the exercise of the 2,265,000 prefunded warrants issued in the public offering, the Company has issued an equal number of common shares, resulting in a total number of shares outstanding as of February 15, 2023 of 5,483,919. As of February 16, 2023, no prefunded warrants remain outstanding.

See the article here:
OpGen Announces Exercise of All Prefunded Warrants

Bright Minds Biosciences Announces Non-Executive Director Appointment

By adminFebruary 18, 2023Global News Feed

David Weiner, MD, brings extensive experience in the discovery and clinical development of novel therapeutics for neurological, psychiatric and rare diseases David Weiner, MD, brings extensive experience in the discovery and clinical development of novel therapeutics for neurological, psychiatric and rare diseases

Follow this link:
Bright Minds Biosciences Announces Non-Executive Director Appointment

NurExone Announces Interim Positive Results of Internal Preclinical Study of Proprietary ExoPTEN Drug

By adminFebruary 18, 2023Global News Feed

ExoPTEN demonstrated motor, reflex and sensory improvement in rats ExoPTEN demonstrated motor, reflex and sensory improvement in rats

See the rest here:
NurExone Announces Interim Positive Results of Internal Preclinical Study of Proprietary ExoPTEN Drug

SciSparc’s Drug Discovery Joint Venture MitoCareX Bio Successfully Reached First Milestone for its Future Machine Learning System

By adminFebruary 18, 2023Global News Feed

MitoCareX established its initial cloud-based computing infrastructure

See the original post:
SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Reached First Milestone for its Future Machine Learning System

Jasper Therapeutics Presents Data Supporting Ongoing Development of Briquilimab, its c-Kit Targeting Antibody, at the 2023 Transplantation &…

By adminFebruary 18, 2023Global News Feed

REDWOOD CITY, Calif., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced new positive Phase 1 data on briquilimab (formerly known as JSP191) in combination with fludarabine and low-dose irradiation (Flu/TBI) conditioning in older adults with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) undergoing allogeneic hematopoietic cell transplant (HCT). The data are being featured in two oral presentations and one poster presentation at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (February 15-19, 2023; Orlando, Florida).

Read more here:
Jasper Therapeutics Presents Data Supporting Ongoing Development of Briquilimab, its c-Kit Targeting Antibody, at the 2023 Transplantation &...

Ocugen to Present at Retinal Vascular Disease Drug Development Summit

By adminFebruary 18, 2023Global News Feed

MALVERN, Pa., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company’s Chief Scientific Officer, Arun Upadhyay, Ph.D., will participate in the Retinal Vascular Disease Drug Development Summit at the Hilton Boston Logan Airport in Boston, Mass. from February 21-23, 2023.

See the original post:
Ocugen to Present at Retinal Vascular Disease Drug Development Summit

AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To…

By adminFebruary 18, 2023Global News Feed

OCALA, Fla., Feb. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — today announced it will participate in an event hosted by Solve M.E. Diagnostics and The Biotechnology Innovation Organization (BIO) titled, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?,” being held virtually on Tuesday, February 21, 2023, from 10:00 AM – 1:00 PM PT.

See the original post:
AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To...

Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia…

By adminFebruary 18, 2023Global News Feed

REDWOOD CITY, Calif., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced that new follow-up data from Jasper’s investigator-sponsored study of briquilimab (formerly known as JSP191) as a conditioning agent in the treatment of Fanconi Anemia (FA) were presented in a poster presentation today at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR taking place in Orlando, Florida.

Here is the original post:
Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia...

Jasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of Directors

By adminFebruary 18, 2023Global News Feed

REDWOOD CITY, Calif., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of healthcare industry veteran Vishal Kapoor, Partner of Avego Management, to Jasper’s Board of Directors.

Continued here:
Jasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of Directors